Effect of adding metronidazole to meropenem on clinical efficacy in complicated intra-abdominal infections: a retrospective study
Hajime Nakashima, Motoyasu Miyazaki, Naoaki Nishimura, Ryo Maeyama, Kenji Yoshikuni, Osamu Imakyure · 2026
Read Effect of adding metronidazole to meropenem on clinical efficacy in complicated intra-abdominal infections: a retrospective study by Hajime Nakashima, Motoyasu Miyazaki, Naoaki Nishimura, Ryo Maeyama, Kenji Yoshikuni, Osamu Imakyure (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13474881.txt.
Description
Nakashima and colleagues asked whether adding a second antibiotic helps patients with severe belly infections in a 2026 review of nine years of hospital cases. Meropenem already covers most gut bacteria, but the anaerobe Bacteroides fragilis, a germ that grows without oxygen, is growing resistant to it. The team compared 114 patients treated with meropenem alone against patients who also got metronidazole, a drug aimed squarely at anaerobes.
Cure rates were nearly identical, at 91.2 percent for meropenem alone and 91.3 percent for the two-drug group in the unmatched comparison. Deaths within 28 days and hospital stay lengths also matched closely, and a matched analysis of 20 patients per group again showed no clear advantage for the extra drug. The authors conclude that adding metronidazole brought no measurable benefit once the infection source was controlled by surgery or drainage in these cases.
Catalog record
| CREATOR | Hajime Nakashima, Motoyasu Miyazaki, Naoaki Nishimura, Ryo Maeyama, Kenji Yoshikuni, Osamu Imakyure |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |